Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.56 |
| ▸ | FPR2 | P25090 | 2/20 | 0.56 |
| ▸ | MYLK | Q15746 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 7/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 4/20 | 0.54 |
| ▸ | THPO | P40225 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28784525 | 0.98 | CDK2 (0.60) | CDK2CA2CA1CA9CYP3A4 | |
| SCHEMBL17441666 | 0.88 | LDHA (0.62) | CDK2CA2CA1CA9CYP3A4 | |
| SCHEMBL9138970 | 0.87 | CDK2 (0.78) | CDK2CA2CA1CA9CYP2C9 | |
| SCHEMBL1808975 | 0.81 | CDK2 (0.55) | CDK2CA2CA1CA9CYP3A4 | |
| SCHEMBL639426 | 0.81 | CYP1A2 (0.56) | CDK2CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL31456881 | 0.81 | CYP1A2 (0.56) | CDK2CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1808977 | 0.80 | CDK2 (0.62) | CDK2CA2CA1CA9CYP1A2 | |
| SCHEMBL14030904 | 0.79 | CYP1A2 (0.54) | CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10577721 | 0.79 | CA2 (0.64) | CDK2CA2CA1CA9CYP2C9 | |
| SCHEMBL3057460 | 0.79 | TTR (0.60) | CDK2CYP3A4CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018154519-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2018-08-30 | — | — | WO | disclosed |
| US-20180244611-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2018-08-30 | — | — | US | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| WO-2016011019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| CN-103764642-A | Substituted vinyl-and alkynyl-cyclohexenols as active substances against abiotic stress in plants | BAYER CROPSCIENCE AG | 2014-04-30 | — | — | CN | disclosed |
| CN-103491776-A | Use of open-chain carboxylic acids, carbonic esters, carboxamides and carbonitriles of aryl, heteroaryl and benzylsulfonamide or the salts thereof for improving the stress tolerance in plants | BAYER CROPSCIENCE AG | 2014-01-01 | — | — | CN | disclosed |
| CN-103476254-A | Use of substituted spirocyclic sulfonamidocarboxylic acids, carboxylic esters thereof, carboxamides thereof and carbonitriles thereof or salts thereof for enhancement of stress tolerance in plants | BAYER CROPSCIENCE AG | 2013-12-25 | — | — | CN | disclosed |
| CN-101812063-A | Alpha-naphthalenesulfonamide base quintuple heterocyclic compound and anti-tumor activity thereof | INST MED BIOTECHNOLOGY CAMS | 2010-08-25 | — | — | CN | disclosed |
| WO-2003059197-A2 | THE USE OF SULFONATED COMPOUNDS AS A BARRIER CONTRACEPTIVE | THE REAGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-07-24 | — | — | WO | disclosed |
| US-5663174-A | ANTIINFLAMMATORY AGENTS, INHIBITOR OF KINASES, ANTIARTHRITIC AGENTS | PHARNO-WEDROPHARM GMBH (DE) | 1997-09-02 | — | — | US | disclosed |
| US-5663174-A | ANTIINFLAMMATORY AGENTS, INHIBITOR OF KINASES, ANTIARTHRITIC AGENTS | PHARNO-WEDROPHARM GMBH (DE) | 1997-09-02 | — | — | US | disclosed |
| EP-0602028-B1 | AROMATIC SULFONAMIDE DERIVATIVES, THEIR USE AS ENZYME INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARNO WEDROPHARM GMBH (DE) | 1996-01-17 | — | — | EP | disclosed |
| EP-0602028-B1 | AROMATIC SULFONAMIDE DERIVATIVES, THEIR USE AS ENZYME INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARNO WEDROPHARM GMBH (DE) | 1996-01-17 | — | — | EP | disclosed |
| EP-0602028-A1 | AROMATIC SULFONAMIDE DERIVATIVES, THEIR USE AS ENZYME INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | PHARNO WEDROPHARM GMBH (DE) | 1994-06-22 | — | — | EP | disclosed |
| EP-0602028-A1 | AROMATIC SULFONAMIDE DERIVATIVES, THEIR USE AS ENZYME INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | PHARNO WEDROPHARM GMBH (DE) | 1994-06-22 | — | — | EP | disclosed |
| WO-1993005014-A1 | AROMATIC SULFONAMIDE DERIVATIVES, THEIR USE AS ENZYME INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARNO-WEDROPHARM GMBH (DE) | 1993-03-18 | — | — | WO | disclosed |
| WO-1993005014-A1 | AROMATIC SULFONAMIDE DERIVATIVES, THEIR USE AS ENZYME INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARNO-WEDROPHARM GMBH (DE) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | BMP1, BMP2, BMPR2 | CDK2 1334/4885CA2 4122/4885CA1 4708/4885 |
| US-20180244611-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, CLCN2, SCNN1G | CDK2 4087/4885CA2 1500/4885CA1 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.